Drugs / Tegileridine
Tegileridine
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07372924 | Feb → Jul 2026 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07844512 | Oct 2026 → Oct 2027 expected | obesity disorder, sleep apnea syndrome | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT07665151 | Jul → Aug 2026 overdue | — | Shiyou Wei | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07678411 | Jul 2026 overdue | upper digestive tract disorder | Shiyou Wei | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07229495 | Jul 2026 → Jun 2027 expected | adolescent idiopathic scoliosis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07637968 | Jun 2026 → Jan 2027 expected | — | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07412223 | Feb → Dec 2026 expected | ileus, neuropathy, painful | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07326683 | Dec 2025 → Jan 2026 | — | Xin Chen | Completed | No outcome recorded |
| Phase 4 | NCT07277153 | Nov 2025 → Mar 2026 | cholecystitis | Xin Chen | Completed | No outcome recorded |
| Phase 4 | NCT07353996 | Oct 2025 → Mar 2026 overdue | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT06458400 | Jul → Sep 2024 | — | Yuwei Qiu | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07386626 | Mar → Dec 2026 expected | — | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegileridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07372924 ↗ |
| Known as | Tegileridine Fumarate | “Tegileridine Fumarate lnjection; low dose” NCT07372924 ↗ |
| Known as | tegileridine fumarate injection | “Tegileridine (tegileridine fumarate injection, IV) is a small-molecule μ-opioid receptor agonist with G-protein-biased signaling (relative to β-arrestin-2 recruitment),...” NCT07277153 ↗2“Tegileridine (tegileridine fumarate injection, IV) is a small-molecule μ-opioid receptor agonist with G-protein-biased signaling (relative to β-arrestin-2 recruitment),...” NCT07326683 ↗ “The pump is filled with a 100 mL mixture of the investigational drug, Tegileridine Fumarate Injection, at a concentration of 0.05 mg/mL, and the adjuvant drug, Dexmedetomidine...” NCT07412223 ↗ |
| Action | Activate | “Tegileridine is a novel μ-opioid receptor-biased agonist.” NCT07229495 ↗ |
| Modality | Small molecule | “Tegileridine (tegileridine fumarate injection, IV) is a small-molecule μ-opioid receptor agonist” NCT07277153 ↗ |
| Route | Intravenous | “The loading iv dose: 0.75mg” NCT06458400 ↗ |